Generex subsidiary, Immune Tolerance Network to develop improved diabetes diagnostic test
WORCESTER, Mass. The Immune Tolerance Network and a company that develops immunotherapeutics have signed an agreement to implement a better diagnostic test for Type 1 diabetes.
Antigen Express, a subsidiary of Generex Biotechnology Corp., said Tuesday that the diagnostic test is based on technology that Antigen Express is developing and that the ability to identify patients with Type 1 diabetes earlier and more accurately would benefit the management of those patients.
Antigen Express’s technology allows for more potent and specific activation of CD4+ T helper cells, both after immunization and using blood cells outside the body. In Type 1 diabetes, also known as juvenile-onset diabetes, the cells become aberrantly activated to recognize proteins associated with cells involved in insulin secretion, leading to the cells’ destruction.
Atherotech’s new cholesterol test showcased at Internal Medicine 2009
BIRMINGHAM, Ala. Atherotech, Inc. announced Monday it will be exhibiting its VAP Cholesterol Test at Internal Medicine 2009, the annual scientific meeting of the American College of Physicians.
The conference takes place April 23 to April 25, at the Pennsylvania Convention Center in Philadelphia.
Used in more than 100 clinical trials, including the Heredity and Phenotype Intervention Heart Study, recently published in Science, the Vertical Auto Profile Test claims to be the most accurate cholesterol test available.
The VAP Test reports 20 separate components of blood cholesterol as opposed to four in a standard test and can identify a far great number of lipid abnormalities (the #1 risk factor for heart disease) than the standard cholesterol test. The test identifies markers for metabolic syndrome, a precursor for diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.
The VAP Test provides physicians and researchers with direct measurement of LDL, HDL and all relevant subclasses, non-HDL and emerging risk factors such as Lp(a), remnants and small dense LDL.
Atherotech recently announced the addition of more than a dozen tests for patients at intermediate to high risk of cardiometabolic diseases. The new test panels are available immediately and also include homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D, fibrinogen and insulin. The tests can be ordered individually, or bundled as part of a custom risk profile that may also include the VAP Test.
People with a family history or an existing condition of diabetes, high blood pressure or heart disease – or who are already taking cholesterol-lowering medication – are candidates for the comprehensive VAP Test.
Sanofi-Aventis announces availability of insulin pen in the United States
BRIDGEWATER, N.J. A disposable insulin pen for patients ages 4 and older with Type 1 diabetes and adults with Type 2 diabetes has become available in the United States.
Sanofi-Aventis U.S. announced Monday the availability of the Apidra SoloSTAR, a pen with the fast-acting insulin analog Apidra (insulin glulisine [rDNA origin]). The pen received Food and Drug Administration approval in February, following the approval and launch of the long-acting Lantus SoloSTAR (insulin glargine [rDNA origin]).
“Sanofi-Aventis is committed to providing innovative tools to patients with diabetes that can help ease some of the challenges of blood sugar management,” stated Jerry Durso, Sanofi-Aventis U.S. VP Specialized Therapeutics Business Unit. “Apidra SoloSTAR provides patients with a convenient option for administering their Apidra.”